Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a leading biotechnology company that specializes in developing and commercializing innovative products targeting the extracellular matrix for the treatment of cancer, diabetes, and other diseases. Leveraging its proprietary enzyme technology, Halozyme enhances the delivery of drugs, positioning itself as a key player in the drug delivery and oncology sectors.
On December 4, 2025, an analyst from UBS set a price target of $56 for HALO, which was notably lower than its current price of $64.66. This target suggests a potential decrease of approximately -13.39% from the stock's current value. Despite this, Halozyme has received a consensus rating of "Moderate Buy" from fourteen analysts, as reported by Marketbeat.com.
The analyst opinions on HALO are mixed. Seven analysts have rated the stock as a hold, while the other seven have given it a buy rating. The average one-year target price set by analysts for Halozyme is $75.10, which is higher than the current price. This indicates that some analysts see potential for growth in the stock.
Several research firms have shared their insights on Halozyme. HC Wainwright reaffirmed their "buy" rating and set a price objective of $90.00. JPMorgan Chase & Co. increased their price target from $63.00 to $65.00, assigning a "neutral" rating. Meanwhile, Morgan Stanley adjusted their price objective from $80.00 to $79.00, maintaining an "overweight" rating.
Currently, HALO's price is $64.66, reflecting a decrease of 2.83% or $1.88. The stock has fluctuated between a low of $64.58 and a high of $67.10 today. Over the past year, HALO has reached a high of $79.50 and a low of $46.26. The company's market capitalization is approximately $7.6 billion, with a trading volume of 2,860,990 shares on the NASDAQ exchange.
